RLYB
$9.65
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-H...
Recent News
Rallybio to acquire Candid Therapeutics
The combined cash balance at closing is projected to fund operations through 2030.
Candid, in a reverse merger with RallyBio, to go public
Candid, which is making bispecifics for immune diseases, has also raised $505 million in a private financing for the newly formed company.
Stock Splits Matter: What’s Coming Up This Month?
Here is a look at why companies split their stocks and why it matters. Upcoming splits worth keeping an eye on include one by Southern Copper.
Does Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)?
In recent days, Recursion Pharmaceuticals attracted heightened attention as traders responded to the stock’s very large short interest, alongside the announcement of a $12.5 million milestone payment from Rallybio related to the advancement of REV102 for hypophosphatasia. An intriguing detail is that Recursion’s AI capabilities have expanded through the co-development of Boltz-2 with MIT, highlighting the company’s ongoing investment in cutting-edge drug discovery technology. We’ll explore...
Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Recursion Pharmaceuticals, Inc. is one of them. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), a clinical-stage biotech, is pioneering the use of artificial intelligence and machine learning to accelerate drug discovery, with a focus on rare diseases and oncology. […]